Ruti Aga Banned for Six Years: A Family Member Forged the Prescription, and a Career Ended

The Athletics Integrity Unit (AIU) has banned Ethiopian marathon runner Ruti Aga for six years. The case of the 32-year-old is unusual not because of the substance at its centre, but because of a forged prescription — a document prepared by a member of her own family and presented as having been issued by a clinic that does not exist. The AIU confirmed the sanction in a statement issued on Thursday. According to the sequence of events, Aga won a half marathon in China in March this year. A sample taken at that competition returned an adverse finding for methylprednisolone. She was provisionally suspended from 10 September, and the six-year ban has now been backdated to the same date. Her finishing time, splits and the strength of the field were not disclosed in the statement, so no performance assessment is possible. The only known fact is that she won the race, which implies a World Athletics Label-tier elite field with in-competition testing. The arithmetic of the sanction is straightforward: two years for the presence violation and four years for tampering with the investigation, six years in total. That 2 + 4 structure indicates the panel found the presence violation proven without aggravating intent, while treating the attempt to mislead investigators through a fabricated document as fully culpable, attracting the Code's standard four-year penalty. In other words, had the prescription been genuine, a legitimate defence route existed. The forgery closed that route. A technical correction is necessary here, because several reports have described methylprednisolone as a prohibited steroid, which is imprecise. It is a glucocorticoid — class S9 on the WADA Prohibited List — not an anabolic steroid (class S1). Under the current List, S9 glucocorticoids are prohibited in-competition only, and only by injection, oral or rectal routes. The direct implication is that the entire case turned not on steroid use but on route of administration and the timing of the injection relative to the competition. A therapeutic knee injection is entirely legal out-of-competition; it becomes a violation only if residues are present in an in-competition sample. That is what makes the case technically interesting and legally fatal at the same time. Intra-articular or peri-articular methylprednisolone for knee synovitis is standard sports-medicine practice in distance runners. But when genuine medical records exist, they are produced as genuine records. Resorting to a forged prescription is itself the signal that no authentic record existed in the first place. According to the AIU, the prescription was presented as issued by a clinic that does not exist; the person described as a doctor was a family member with no medical registration; and he claimed to have used an old prescription pad from a former workplace, which the clinic in question explicitly disowned. Three independent layers of verification failed at once. The case signals a broader medical-governance failure inside East African road-racing entourages. An athlete with a credentialed team physician would either have held or applied for a Therapeutic Use Exemption, or observed WADA's route-specific washout period. Neither happened here. The pressure to mask injury is also real — injured marathoners face strong incentives to hide pain to protect appearance-fee income and contracts, and glucocorticoids are the cheapest, most readily available tool for that. The forgery is downstream of an unregulated medical ecosystem, not an isolated lapse. It is also worth noting that the four-year tampering sanction arose from an interview, meaning from statements made under questioning, not from a document alone. In career terms, the sanction is close to a career death sentence. A six-year ban running from 10 September removes her from the 2028 Olympic cycle entirely. At the point of a possible return she will be around 38, and the depth of Ethiopian women's marathon running is such that a 38-year-old with a doping record is effectively unselectable for the national team. Interestingly, her historic results are not automatically annulled — the violation is anchored to a later competition, so the 2026 Tokyo Marathon title and three second-place finishes at World Marathon Majors remain on the record. The statement does not specify the scope of disqualification, although under standard AIU practice the result and prize money from the March race, along with ranking points accrued thereafter, should be treated as void. The competitive landscape is essentially unaffected. Ethiopia's depth in women's marathon running is so extreme that the removal of a 32-year-old changes nothing in national selection arithmetic — Aga holds no world championship or Olympic medal, and her three Major runner-up finishes are commercial-tier results rather than championship conversions. The real shift is at the level of the integrity regime. The clustering of tampering charges in recent AIU road-running cases points to a clear pattern: the enforcement frontier has moved from detection to document verification. Aga's case is not an outlier but part of a recognisable family of East African road-racing cases in which an initial substance violation is compounded by a fabricated explanation. More such cases are likely, because the same informal medical networks serve many athletes within the same training clusters. China's label-race circuit has now become a high-scrutiny zone. Large appearance-fee budgets, deep East African elite fields and AIU testing presence combine to attach integrity risk to results at this tier. Aga's win came in exactly that category of race, where the in-competition testing window opens at 23:59 the night before, meaning a glucocorticoid injection given days earlier can still be caught. The appearance-fee economy and the testing economy are now colliding in the same races. An appeal remains possible but is weak. The CAS window is typically around 21 days from the reasoned decision, but the forgery finding rests on documentary evidence and is hard to overturn. There is also potential criminal exposure at national level over the document forgery, which sits outside AIU jurisdiction and was not addressed in the statement. The conclusion is clear: this is not a story about performance but about governance failure. A six-year ban for a glucocorticoid — a substance with no proven endurance benefit — is a striking outcome in itself. It will be cited both as evidence of AIU rigour and as evidence of disproportionate enforcement against African road runners. What is beyond dispute is that Aga ended her career not through a substance, but through her own decisions.